Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2 - PubMed (original) (raw)
Comparative Study
. 1999 May;19(5):1284-90.
doi: 10.1161/01.atv.19.5.1284.
L W Castellani, X P Wang, J H Qiao, M Mehrabian, M Navab, A M Fogelman, D S Grass, M E Swanson, M C de Beer, F de Beer, A J Lusis
Affiliations
- PMID: 10323781
- DOI: 10.1161/01.atv.19.5.1284
Comparative Study
Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2
B Ivandic et al. Arterioscler Thromb Vasc Biol. 1999 May.
Abstract
Some observations have suggested that the extracellular group IIa phospholipase A2 (sPLA2), previously implicated in chronic inflammatory conditions such as arthritis, may contribute to atherosclerosis. We have examined this hypothesis by studying transgenic mice expressing the human enzyme. Compared with nontransgenic littermates, the transgenic mice exhibited dramatically increased atherosclerotic lesions when maintained on a high-fat, high-cholesterol diet. Surprisingly, the transgenic mice also exhibited significant atherosclerotic lesions when maintained on a low-fat chow diet. Immunohistochemical staining indicated that sPLA2 was present in the atherosclerotic lesions of the transgenic mice. On both chow and atherogenic diets, the transgenic mice exhibited decreased levels of HDLs and slightly increased levels of LDLs compared with nontransgenic littermates. These data indicate that group IIa sPLA2 may promote atherogenesis, in part, through its effects on lipoprotein levels. These data also provide a possible mechanism for the observation that there is an increased incidence of coronary artery disease in many chronic inflammatory diseases.
Similar articles
- Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids.
Leitinger N, Watson AD, Hama SY, Ivandic B, Qiao JH, Huber J, Faull KF, Grass DS, Navab M, Fogelman AM, de Beer FC, Lusis AJ, Berliner JA. Leitinger N, et al. Arterioscler Thromb Vasc Biol. 1999 May;19(5):1291-8. doi: 10.1161/01.atv.19.5.1291. Arterioscler Thromb Vasc Biol. 1999. PMID: 10323782 - Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice.
Webb NR, Bostrom MA, Szilvassy SJ, van der Westhuyzen DR, Daugherty A, de Beer FC. Webb NR, et al. Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):263-8. doi: 10.1161/01.atv.0000051701.90972.e5. Arterioscler Thromb Vasc Biol. 2003. PMID: 12588769 - Increased hepatic cholesterol accumulation in transgenic mice overexpressing human secretory phospholipase A2 group IIA.
Eckey R, Menschikowski M, Lattke P, Jaross W. Eckey R, et al. Inflammation. 2004 Apr;28(2):59-65. doi: 10.1023/b:ifla.0000033021.44105.9c. Inflammation. 2004. PMID: 15379211 - Secretory phospholipase A2 enzymes in atherogenesis.
Webb NR. Webb NR. Curr Opin Lipidol. 2005 Jun;16(3):341-4. doi: 10.1097/01.mol.0000169355.20395.55. Curr Opin Lipidol. 2005. PMID: 15891396 Review. - New phospholipase A(2) isozymes with a potential role in atherosclerosis.
Murakami M, Kudo I. Murakami M, et al. Curr Opin Lipidol. 2003 Oct;14(5):431-6. doi: 10.1097/00041433-200310000-00003. Curr Opin Lipidol. 2003. PMID: 14501581 Review.
Cited by
- Regulatory Roles of Phospholipase A2 Enzymes and Bioactive Lipids in Mast Cell Biology.
Taketomi Y, Murakami M. Taketomi Y, et al. Front Immunol. 2022 Jun 27;13:923265. doi: 10.3389/fimmu.2022.923265. eCollection 2022. Front Immunol. 2022. PMID: 35833146 Free PMC article. Review. - The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002).
Shaposhnik Z, Wang X, Trias J, Fraser H, Lusis AJ. Shaposhnik Z, et al. J Lipid Res. 2009 Apr;50(4):623-9. doi: 10.1194/jlr.M800361-JLR200. Epub 2008 Nov 21. J Lipid Res. 2009. PMID: 19029066 Free PMC article. - Role of secretory phospholipase a(2) in CNS inflammation: implications in traumatic spinal cord injury.
Titsworth WL, Liu NK, Xu XM. Titsworth WL, et al. CNS Neurol Disord Drug Targets. 2008 Jun;7(3):254-69. doi: 10.2174/187152708784936671. CNS Neurol Disord Drug Targets. 2008. PMID: 18673210 Free PMC article. Review. - Proteolysis of apolipoprotein A-I by secretory phospholipase A₂: a new link between inflammation and atherosclerosis.
Cavigiolio G, Jayaraman S. Cavigiolio G, et al. J Biol Chem. 2014 Apr 4;289(14):10011-23. doi: 10.1074/jbc.M113.525717. Epub 2014 Feb 12. J Biol Chem. 2014. PMID: 24523407 Free PMC article. Clinical Trial. - Secretory phospholipase A2, group IIA is a novel serum amyloid A target gene: activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism.
Sullivan CP, Seidl SE, Rich CB, Raymondjean M, Schreiber BM. Sullivan CP, et al. J Biol Chem. 2010 Jan 1;285(1):565-75. doi: 10.1074/jbc.M109.070565. Epub 2009 Oct 22. J Biol Chem. 2010. PMID: 19850938 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases